vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Kennedy-Wilson Holdings, Inc. (KW). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $120.6M, roughly 1.2× Kennedy-Wilson Holdings, Inc.). Kennedy-Wilson Holdings, Inc. runs the higher net margin — 48.1% vs 35.5%, a 12.6% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -11.0%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-55.2M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -6.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Kennedy Wilson is a real estate investment company headquartered in Beverly Hills, California, United States.
ADMA vs KW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $120.6M |
| Net Profit | $49.4M | $58.0M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 57.3% |
| Net Margin | 35.5% | 48.1% |
| Revenue YoY | 18.4% | -11.0% |
| Net Profit YoY | -55.9% | 32.7% |
| EPS (diluted) | $0.20 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $120.6M | ||
| Q3 25 | $134.2M | $116.4M | ||
| Q2 25 | $122.0M | $135.7M | ||
| Q1 25 | $114.8M | $128.3M | ||
| Q4 24 | $117.5M | $135.5M | ||
| Q3 24 | $119.8M | $127.5M | ||
| Q2 24 | $107.2M | $132.0M | ||
| Q1 24 | $81.9M | $136.4M |
| Q4 25 | $49.4M | $58.0M | ||
| Q3 25 | $36.4M | $-10.2M | ||
| Q2 25 | $34.2M | $5.6M | ||
| Q1 25 | $26.9M | $-29.6M | ||
| Q4 24 | $111.9M | $43.7M | ||
| Q3 24 | $35.9M | $-66.8M | ||
| Q2 24 | $32.1M | $-48.3M | ||
| Q1 24 | $17.8M | $37.7M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 57.3% | ||
| Q3 25 | 38.0% | -6.2% | ||
| Q2 25 | 35.1% | 7.4% | ||
| Q1 25 | 30.4% | -26.9% | ||
| Q4 24 | 32.6% | 36.7% | ||
| Q3 24 | 33.1% | -60.8% | ||
| Q2 24 | 36.6% | -45.5% | ||
| Q1 24 | 26.7% | 47.2% |
| Q4 25 | 35.5% | 48.1% | ||
| Q3 25 | 27.1% | -8.8% | ||
| Q2 25 | 28.1% | 4.1% | ||
| Q1 25 | 23.4% | -23.1% | ||
| Q4 24 | 95.2% | 32.3% | ||
| Q3 24 | 30.0% | -52.4% | ||
| Q2 24 | 29.9% | -36.6% | ||
| Q1 24 | 21.7% | 27.6% |
| Q4 25 | $0.20 | $0.22 | ||
| Q3 25 | $0.15 | $-0.15 | ||
| Q2 25 | $0.14 | $-0.05 | ||
| Q1 25 | $0.11 | $-0.30 | ||
| Q4 24 | $0.45 | $0.24 | ||
| Q3 24 | $0.15 | $-0.56 | ||
| Q2 24 | $0.13 | $-0.43 | ||
| Q1 24 | $0.08 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $184.5M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.5B |
| Total Assets | $624.2M | $6.6B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $184.5M | ||
| Q3 25 | $61.4M | $382.6M | ||
| Q2 25 | $90.3M | $309.1M | ||
| Q1 25 | $71.6M | $356.6M | ||
| Q4 24 | $103.1M | $217.5M | ||
| Q3 24 | $86.7M | $367.1M | ||
| Q2 24 | $88.2M | $366.5M | ||
| Q1 24 | $45.3M | $541.9M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $1.5B | ||
| Q3 25 | $431.2M | $1.5B | ||
| Q2 25 | $398.3M | $1.6B | ||
| Q1 25 | $373.4M | $1.6B | ||
| Q4 24 | $349.0M | $1.6B | ||
| Q3 24 | $231.9M | $1.6B | ||
| Q2 24 | $188.3M | $1.7B | ||
| Q1 24 | $153.7M | $1.7B |
| Q4 25 | $624.2M | $6.6B | ||
| Q3 25 | $568.7M | $6.7B | ||
| Q2 25 | $558.4M | $6.8B | ||
| Q1 25 | $510.6M | $7.2B | ||
| Q4 24 | $488.7M | $7.0B | ||
| Q3 24 | $390.6M | $7.4B | ||
| Q2 24 | $376.4M | $7.5B | ||
| Q1 24 | $350.9M | $7.7B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $11.4M |
| Free Cash FlowOCF − Capex | $34.6M | $-55.2M |
| FCF MarginFCF / Revenue | 24.8% | -45.8% |
| Capex IntensityCapex / Revenue | 0.8% | 55.2% |
| Cash ConversionOCF / Net Profit | 0.72× | 0.20× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-103.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $11.4M | ||
| Q3 25 | $13.3M | $-7.6M | ||
| Q2 25 | $21.1M | $42.0M | ||
| Q1 25 | $-19.7M | $-51.9M | ||
| Q4 24 | $50.2M | $55.1M | ||
| Q3 24 | $25.0M | $-5.6M | ||
| Q2 24 | $45.6M | $36.7M | ||
| Q1 24 | $-2.2M | $-5.6M |
| Q4 25 | $34.6M | $-55.2M | ||
| Q3 25 | $-1.1M | $-18.0M | ||
| Q2 25 | $18.7M | $29.4M | ||
| Q1 25 | $-24.4M | $-59.7M | ||
| Q4 24 | $47.5M | $-76.5M | ||
| Q3 24 | $24.0M | $-27.7M | ||
| Q2 24 | $43.6M | $-500.0K | ||
| Q1 24 | $-4.6M | $-57.1M |
| Q4 25 | 24.8% | -45.8% | ||
| Q3 25 | -0.8% | -15.5% | ||
| Q2 25 | 15.3% | 21.7% | ||
| Q1 25 | -21.2% | -46.5% | ||
| Q4 24 | 40.4% | -56.5% | ||
| Q3 24 | 20.0% | -21.7% | ||
| Q2 24 | 40.7% | -0.4% | ||
| Q1 24 | -5.6% | -41.9% |
| Q4 25 | 0.8% | 55.2% | ||
| Q3 25 | 10.7% | 8.9% | ||
| Q2 25 | 2.0% | 9.3% | ||
| Q1 25 | 4.1% | 6.1% | ||
| Q4 24 | 2.3% | 97.1% | ||
| Q3 24 | 0.9% | 17.3% | ||
| Q2 24 | 1.9% | 28.2% | ||
| Q1 24 | 2.9% | 37.8% |
| Q4 25 | 0.72× | 0.20× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 7.50× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 1.26× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | -0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
KW
| Consolidated Portfolio Segment | $84.9M | 70% |
| Investment Management Fees | $30.4M | 25% |
| Real Estate | $5.1M | 4% |
